



Application of Nanoparticles in Cancer Therapy and Diagnosis

Guest Editors:

**Dr. Liane Isabel Ferreira
Moura**

BioNanoSciences—Drug Delivery
& Immunotherapy Group,
Research Institute for Medicines
(iMed.U LISBOA), Faculty of
Pharmacy, University of Lisbon,
Lisbon, Portugal

Dr. Murtaza M. Tambuwala

School of Pharmacy and
Pharmaceutical Science, Ulster
University, Coleraine BT52 1SA,
UK

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editors

Several studies have demonstrated that the trapping of anticancer medications in submicronic colloidal systems, such as nanoparticles, can help to regulate both the tissue and cell distribution characteristics of these treatments. Additionally, nanoparticles are useful for the targeted delivery of oligonucleotides to tumour cells. Furthermore, several types of nanoparticles have shown an intriguing ability to overcome MDR resistance. Polymeric nanoparticles, liposomes, dendrimers, nano-shells, carbon nanotubes, superparamagnetic nanoparticles, and nucleic acid-based nanoparticles are examples of current nanotechnology platforms used for anticancer drug delivery. Recently, nanotechnologies are also being used in combination therapeutic strategies, such as ultrasound, hyperthermia, or photodynamic therapy. Decorating nanoparticles with a molecular ligand for the 'active' targeting of cancerous cells is considered as the next step in developing better cancer targeting strategies using nanoparticles. Applying nanoparticles in imaging for cancer diagnosis could lead to early detection and, consequently, improved cancer management.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma